Generated by AI
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also works with proprietary formulation technologies designed to support liquid-stable, ready-to-use injectable medicines and reduce preparation steps for patients and caregivers. Its business is centered on specialty pharmaceuticals that address complex, often long-term conditions in endocrinology, neurology, and related areas, with a focus on patient-friendly delivery formats and commercial therapies already in market.
Website1375 West Fulton Street
Chicago, IL, 60607
United States
The latest articles about XERS.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Dec 31's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Investors talking about XERS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.